Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | HPGD | P15428 | 8/20 | 0.53 |
| ▸ | GAA | P10253 | 7/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | CASP1 | P29466 | 5/20 | 0.53 |
| ▸ | CASP7 | P55210 | 5/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 6/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033387 | 0.84 | KDM4E (0.43) | POLBCYP1A2KDM4EALDH1A1HPGD | |
| SCHEMBL12247506 | 0.84 | KDM4E (0.57) | POLBCYP1A2KDM4EALDH1A1HPGD | |
| SCHEMBL13802956 | 0.84 | KDM4E (0.54) | POLBCYP1A2KDM4EALDH1A1HPGD | |
| SCHEMBL5430464 | 0.81 | KDM4E (0.50) | POLBCYP1A2KDM4EALDH1A1HPGD | |
| SCHEMBL5434270 | 0.81 | KDM4E (0.50) | POLBKDM4EALDH1A1HPGDGAA | |
| SCHEMBL9073054 | 0.81 | MAPT (0.56) | POLBKDM4EALDH1A1HPGDGAA | |
| Bromide SCHEMBL9069438 | 0.79 | MAPT (0.54) | POLBKDM4EALDH1A1HPGDGAA | |
| SCHEMBL874427 | 0.79 | POLB (0.66) | POLBCYP1A2KDM4EALDH1A1MAPT | |
| SCHEMBL14960133 | 0.76 | POLB (0.61) | POLBCYP1A2KDM4EALDH1A1HPGD | |
| SCHEMBL6639402 | 0.76 | POLB (0.61) | POLBCYP1A2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| CN-100360505-C | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2008-01-09 | — | — | CN | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-1154774-B1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| CN-1597667-A | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2005-03-23 | — | — | CN | disclosed |
| CN-1167422-C | Quinazoline derivatives as angiogenesis inhibitors | — | 2004-09-22 | — | — | CN | disclosed |
| CN-1346271-A | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA UK LTD (SE) | 2002-04-24 | — | — | CN | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| US-4169183-A | 9-Dialkylamino-spiro [6H-[1]benzopyrano[3,2-g]quinoline-6,1'(3'H)-isobenzofuran]-3'-one compounds and pressure-sensitive recording system therewith | MOORE BUSINESS FORMS, INC. (US) | 1979-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | POLB 2945/4885CYP1A2 807/4885KDM4E 2055/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | POLB 3959/4885CYP1A2 2646/4885KDM4E 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.